FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3099100880> ?p ?o ?g. }

• W3099100880 abstract "Background CV8102 is a non-coding, non-capped RNA complexed with a carrier peptide activating the innate (via TLR7/8, RIG-I) and adaptive immune system. 1 2 An ongoing phase I trial is investigating i.t. CV8102 either as a single agent or in combination with systemic anti-PD-1 antibodies in patients with advanced melanoma (MEL), squamous cell carcinoma of the skin (cSCC) or head and neck (hnSCC) and adenoid cystic carcinoma (ACC). Methods An open-label, cohort-based, dose escalation and expansion study in patients with advanced cutaneous melanoma (cMEL), cutaneous squamous cell carcinoma (cSCC), head and neck squamous cell carcinoma (hnSCC) or adenoid cystic carcinoma (ACC) is ongoing investigating i.t. CV8102 as single agent and in combination with anti-PD-1 antibodies. 8 intratumoral injections of CV8102 are being administered initially over a 12 week period, while patients benefiting from the single agent therapy may receive further treatment. In an initial dose escalation part the maximum tolerated dose and recommended phase 2 dose for subsequent cohort expansion will be defined. Results As of September 16, 2020, 29 patients have been treated with CV8102 as a single agent (25-900 µg) and 21 patients have received CV8102 (25-900 µg) in combination with anti-PD-1 antibodies. Most frequent treatment related adverse events were mild to moderate fever, fatigue, chills and headache. One patient treated at the 900 µg single agent experienced a dose limiting toxicity (G3 transaminase increase in the context of G2 cytokine release syndrome). Regression of injected and distant noninjected lesions was observed in several patients in the single agent and the anti-PD-1 combination cohorts. Updated safety and efficacy results will be presented. Conclusions CV8102 showed an acceptable tolerability and preliminary evidence of clinical efficacy as single agent and in combination with anti-PD-1- antibodies. Trial Registration NCT03291002 Ethics Approval The study was approved by the Central Ethics Committees in Tuebingen, Germany under 785/2016AMG1, in France under 19.05.17.64111, in Barcelona, Spain under the EudraCT number. Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. References Ziegler A, Soldner C, Lienenklaus S, Spanier J, Trittel S, Riese P, Kramps T, Weiss S, Heidenreich R, Jasny E, Guzmán CA, Kallen KJ, Fotin-Mleczek M, Kalinke U. A new RNA-based adjuvant enhances virus-specific vaccine responses by locally triggering TLR- and RLH-dependent effects. J Immunol 2017;198(4):1595-1605. doi:10.4049/jimmunol.1601129 Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, Scheel B, Voss S, Kallen KJ, Fotin-Mleczek M. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int J Cancer 2015 Jul 15;137(2):372-84. doi: 10.1002/ijc.29402" @default.
• W3099100880 created "2020-11-23" @default.
• W3099100880 creator A5002605575 @default.
• W3099100880 creator A5004458225 @default.
• W3099100880 creator A5004881462 @default.
• W3099100880 creator A5007662797 @default.
• W3099100880 creator A5014277422 @default.
• W3099100880 creator A5014935719 @default.
• W3099100880 creator A5021736614 @default.
• W3099100880 creator A5025478490 @default.
• W3099100880 creator A5033334588 @default.
• W3099100880 creator A5040652983 @default.
• W3099100880 creator A5042724544 @default.
• W3099100880 creator A5044089291 @default.
• W3099100880 creator A5046038895 @default.
• W3099100880 creator A5048979897 @default.
• W3099100880 creator A5054682698 @default.
• W3099100880 creator A5054698965 @default.
• W3099100880 creator A5056227404 @default.
• W3099100880 creator A5058642751 @default.
• W3099100880 creator A5071942259 @default.
• W3099100880 creator A5077195427 @default.
• W3099100880 creator A5082719401 @default.
• W3099100880 date "2020-11-01" @default.
• W3099100880 modified "2023-10-18" @default.
• W3099100880 title "800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors" @default.
• W3099100880 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0800" @default.
• W3099100880 hasPublicationYear "2020" @default.
• W3099100880 type Work @default.
• W3099100880 sameAs 3099100880 @default.
• W3099100880 citedByCount "1" @default.
• W3099100880 countsByYear W30991008802023 @default.
• W3099100880 crossrefType "proceedings-article" @default.
• W3099100880 hasAuthorship W3099100880A5002605575 @default.
• W3099100880 hasAuthorship W3099100880A5004458225 @default.
• W3099100880 hasAuthorship W3099100880A5004881462 @default.
• W3099100880 hasAuthorship W3099100880A5007662797 @default.
• W3099100880 hasAuthorship W3099100880A5014277422 @default.
• W3099100880 hasAuthorship W3099100880A5014935719 @default.
• W3099100880 hasAuthorship W3099100880A5021736614 @default.
• W3099100880 hasAuthorship W3099100880A5025478490 @default.
• W3099100880 hasAuthorship W3099100880A5033334588 @default.
• W3099100880 hasAuthorship W3099100880A5040652983 @default.
• W3099100880 hasAuthorship W3099100880A5042724544 @default.
• W3099100880 hasAuthorship W3099100880A5044089291 @default.
• W3099100880 hasAuthorship W3099100880A5046038895 @default.
• W3099100880 hasAuthorship W3099100880A5048979897 @default.
• W3099100880 hasAuthorship W3099100880A5054682698 @default.
• W3099100880 hasAuthorship W3099100880A5054698965 @default.
• W3099100880 hasAuthorship W3099100880A5056227404 @default.
• W3099100880 hasAuthorship W3099100880A5058642751 @default.
• W3099100880 hasAuthorship W3099100880A5071942259 @default.
• W3099100880 hasAuthorship W3099100880A5077195427 @default.
• W3099100880 hasAuthorship W3099100880A5082719401 @default.
• W3099100880 hasConcept C143998085 @default.
• W3099100880 hasConcept C159654299 @default.
• W3099100880 hasConcept C203014093 @default.
• W3099100880 hasConcept C502942594 @default.
• W3099100880 hasConcept C71924100 @default.
• W3099100880 hasConcept C98274493 @default.
• W3099100880 hasConceptScore W3099100880C143998085 @default.
• W3099100880 hasConceptScore W3099100880C159654299 @default.
• W3099100880 hasConceptScore W3099100880C203014093 @default.
• W3099100880 hasConceptScore W3099100880C502942594 @default.
• W3099100880 hasConceptScore W3099100880C71924100 @default.
• W3099100880 hasConceptScore W3099100880C98274493 @default.
• W3099100880 hasLocation W30991008801 @default.
• W3099100880 hasOpenAccess W3099100880 @default.
• W3099100880 hasPrimaryLocation W30991008801 @default.
• W3099100880 hasRelatedWork W1506200166 @default.
• W3099100880 hasRelatedWork W2039318446 @default.
• W3099100880 hasRelatedWork W2048182022 @default.
• W3099100880 hasRelatedWork W2080531066 @default.
• W3099100880 hasRelatedWork W2748952813 @default.
• W3099100880 hasRelatedWork W2897496508 @default.
• W3099100880 hasRelatedWork W2899084033 @default.
• W3099100880 hasRelatedWork W2998699411 @default.
• W3099100880 hasRelatedWork W3032375762 @default.
• W3099100880 hasRelatedWork W3108674512 @default.
• W3099100880 isParatext "false" @default.
• W3099100880 isRetracted "false" @default.
• W3099100880 magId "3099100880" @default.
• W3099100880 workType "article" @default.